Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Lymphoma
Leukemia

Interventions: Biological: anti-thymocyte globulin
Biological: filgrastim
Biological: graft-versus-tumor induction therapy
Biological: rituximab
Drug: cyclophosphamide
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: mycophenolate mofetil
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Radiation: total-body irradiation

First Posted Date: 2007-01-23

Last Posted Date: 2017-10-31

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 61

Registration Number: NCT00425802

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Conditions: Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Precancerous Condition
Secondary Myelofibrosis

First Posted Date: 2007-01-18

Last Posted Date: 2016-02-29

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT00423826

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Allogeneic Blood Stem Cell Transplantation

Not Applicable

Completed

Conditions: Hodgkin's Disease

First Posted Date: 2007-01-18

Last Posted Date: 2012-01-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 46

Registration Number: NCT00423709

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML

Phase 2

Terminated

Conditions: Leukemia

Interventions: Drug: Campath
Drug: Fludarabine
Radiation: Total Body Irradiation (TBI)
Other: T-Cell Deplete

First Posted Date: 2006-12-28

Last Posted Date: 2017-09-27

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 1

Registration Number: NCT00416884

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Phase 3

Terminated

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Fludarabine
Biological: Filgrastim
Drug: Cyclophosphamide
Drug: Mitoxantrone

First Posted Date: 2006-12-28

Last Posted Date: 2016-09-26

Lead Sponsor: German CLL Study Group

Target Recruit Count: 83

Registration Number: NCT00416910

Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)

Phase 3

Completed

Conditions: Acute Lymphocytic Leukemia
Chronic Myelogenous Leukemia
Natural Killer Cell Lymphoblastic Leukemia/Lymphoma
Myelodysplastic Syndrome
Acute Myelogenous Leukemia

Interventions: Biological: Single Umbilical Cord Blood Unit Transplant
Biological: Double Umbilical Cord Blood Unit Transplant
Radiation: Total Body Irradiation
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Cyclosporine A
Drug: Mycophenolate Mofetil

First Posted Date: 2006-12-18

Last Posted Date: 2021-10-28

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 224

Registration Number: NCT00412360

Locations: 🇺🇸
University of Mississippi, Jackson, Mississippi, United States
🇺🇸
Children's Medical Center of Dallas, Dallas, Texas, United States
🇺🇸
New York Medical College, Valhalla, New York, United States

and more 35 locations

Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients

Phase 2

Completed

Conditions: Leukaemia, Lymphocytic, Chronic

Interventions: Drug: Ofatumumab 500mg
Drug: Ofatumumab 1000mg
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2006-12-12

Last Posted Date: 2014-02-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 61

Registration Number: NCT00410163

Locations: 🇬🇧
GSK Investigational Site, Plymouth, Devon, United Kingdom

Stem Cell Transplant in Sickle Cell Disease and Thalassemia

Phase 2

Active, not recruiting

Conditions: Sickle Cell Disease
Beta Thalassemia

Interventions: Drug: Busulfan
Drug: Fludarabine
Drug: Alemtuzumab
Procedure: Allogeneic stem cell transplant

First Posted Date: 2006-12-07

Last Posted Date: 2024-06-13

Lead Sponsor: Columbia University

Target Recruit Count: 53

Registration Number: NCT00408447

Locations: 🇺🇸
Morgan Stanley Children's Hospital, New York-Presbyterian, Columbia University, New York, New York, United States

Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Phase 1

Completed

Conditions: Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Thymoglobulin
Drug: Busulfan
Drug: Fludarabine
Procedure: Alloreactive NK Infusion
Drug: G-CSF
Drug: Tacrolimus
Drug: Methotrexate
Drug: Interleukin-2

First Posted Date: 2006-11-22

Last Posted Date: 2015-05-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT00402558

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma

Phase 1

Conditions: Lymphoma

First Posted Date: 2006-11-10

Last Posted Date: 2012-08-28

Lead Sponsor: Technical University of Munich

Target Recruit Count: 12

Registration Number: NCT00397800

Locations: 🇩🇪
Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg, Magdeburg, Germany
🇩🇪
Universitatsklinik Mainz, Mainz, Germany
🇩🇪
LMU-Klinikum Grosshadern, Munich, Germany

and more 9 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy